Crystal Adam sold $799K of TNGX
Crystal Adam (President, R&D) sold 27,000 shares of Tango Therapeutics, Inc. (TNGX) at an average of $29.59 ($29.34–$30.25, $0.80M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider trading record with exact trade dates, share counts, and prices, but does not provide new operational/financial guidance.
Market read
A single insider sale (~$798,908) under a 10b5-1 plan is typically a low-signal event for price, but it can influence short-term sentiment.
What to watch
Traders may overreact to insider sales; the more informative signal would be whether there are concurrent purchases by other insiders or a pattern of sales outside scheduled windows.
Background
The filing is an SEC Form 4 insider transaction by Crystal Adam (President, R&D) for Tango Therapeutics.
Ticker impact
Tango Therapeutics insider Crystal Adam sold ~$799K of TNGX stock via open-market trades under a 10b5-1 plan on 2026-07-01.
Likely limited/short-lived impact; watch for follow-on insider activity or unusual volume rather than expecting a durable repricing.
Form 4 provides a primary-source transaction and size (~27,000 shares) but explicitly indicates a pre-arranged 10b5-1 plan, reducing inference of new negative information.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- companyTango Therapeutics, Inc.
Issuer of the insider sale disclosed on SEC Form 4 (TNGX).
- insiderCrystal Adam
President, R&D who sold 27,000 shares across two open-market trades under a 10b5-1 plan.